Now showing items 1-1 of 1
A phase I trial of hypoxoside as an oral prodrug for cancer therapy : absence of toxicity
(Health & Medical Publishing Group, 1995)
Objective. To assess the toxicity of hypoxoside taken orally by 24 patients with lung cancer. Design. Open study with patients taking 1 200 - 3 200 mg standardised Hypoxis plant extract (200 mg capsules) per day divided ...